Janux Therapeutics, Inc. JANX
Set alert
17.80 USD +0.34 +1.95%
As of Nov 3, 9:55 AM ET
17.60 Day range 18.00
12.12 52-week range 35.34
- YTD
- +28.99%
- 1 year
- -34.97%
- Open
- 17.60
- Prev close
- 17.46
- Mkt cap
- 1.09B
- Vol
- 49.71K
- Avg vol
- 824.72K
- EPS
- -1.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.60
- High
- 18.00
- Forward P/E
- -6.65
- Beta
- 2.39
- Short ratio
- 5.72
- Inst. own
- 101.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 17.60
- 200-d avg
- 15.33
- 1y target
- 33.81
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 33.81 +90.0% upside
Now 17.80
- Target (low)
- 14.00
- Target (mean)
- 33.81
- Target (high)
- 60.00
Ratings (0m) 18 16 buy · 1 hold · 1 sell
- Strong buy2
- Buy14
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 18
- 1 month ago 18
- 2 months ago 18
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.48843 | -0.67 – -0.04 | -0.39 | -25.2% | 6.42M | -35.8% | 14 |
| Next quarter | -0.56605 | -0.808 – -0.32 | -0.51 | -11.0% | 7.34M | 0.0% | 14 |
| Current year | -1.73 | -2.29 – -0.97 | -1.83 | +5.4% | 29.42M | +194.2% | 14 |
| Next year | -2.62 | -3.17 – -2.06 | -1.73 | -51.5% | 8.10M | -72.5% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 8, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| May 8, 2026 | Wedbush | Maintained | Outperform | Outperform |
| May 8, 2026 | Guggenheim | Maintained | Buy | Buy |
| Apr 28, 2026 | Jones Trading | Maintained | Buy | Buy |
| Apr 20, 2026 | Barclays | Downgrade | Overweight | Underweight |
| Apr 15, 2026 | UBS | Downgrade | Buy | Neutral |
| Feb 27, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Feb 27, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jan 20, 2026 | Clear Street | Downgrade | Buy | Hold |
| Jan 16, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 17, 2025 | Barclays | Maintained | Overweight | Overweight |
| Dec 2, 2025 | Stifel | Maintained | Buy | Buy |
| Dec 2, 2025 | Clear Street | Maintained | Buy | Buy |
| Dec 2, 2025 | B of A Securities | Maintained | Buy | Buy |
| Dec 2, 2025 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Dec 2, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 25, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 18, 2025 | Wolfe Research | Initiated | — | Peer Perform |
| Nov 7, 2025 | Barclays | Maintained | Overweight | Overweight |
| Sep 17, 2025 | Barclays | Initiated | — | Overweight |
| Sep 10, 2025 | Truist Securities | Initiated | — | Buy |
| Sep 4, 2025 | Guggenheim | Initiated | — | Buy |
| Aug 19, 2025 | Piper Sandler | Initiated | — | Overweight |
| Jul 11, 2025 | Raymond James | Initiated | — | Outperform |
| Mar 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 28, 2025 | Scotiabank | Maintained | Sector Perform | Sector Perform |
| Dec 11, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Dec 4, 2024 | Scotiabank | Maintained | Sector Perform | Sector Perform |